Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody

OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 /PRNewswire/ -- Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases. Aditum Bio will fund Oblenio Bio and the parties will collaborate to rapidly bring LBL-051 into clinical studies.

Recent clinical data from CD19 and BCMA targeted therapies have demonstrated compelling efficacy in difficult-to-treat autoimmune diseases. ...

Full story available on Benzinga.com